Unresectable or metastatic urothelial carcinoma treated with systemic chemotherapy
Conditions
Interventions
None listed
Sponsors
Department of Urology, Tsukuba University Hospital
Tsukuba Clinical Research &
Development Organization
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with histologically diagnosed urothelial carcinoma (*). 2. Patients with unresectable or metastatic urothelial carcinoma. 3. Patients treated with the 1st-line systemic chemotherapy from January 1, 2004 to December 31, 2010. 4. Aged 20 or older. *) Include ureteropelvic cancer which clinically diagnosed as urothelial carcinoma by cytologic and imaging diagnosis.
Exclusion criteria
Exclusion criteria: 1. Patients given the first systemic chemotherapy before December 31, 2003. 2. Patients with active cancers in other organs at the start of systemic chemotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of dose modification in the 1st-line chemotherapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The rate of regimen modification in the 1st-line chemotherapy. 2. Response rate in the 1st-line chemotherapy. 3. Overall survival rate. 4. Cancer-specific survival rate 5. Frequency of adverse effects. 6. Response rate in the 2nd-line chemotherapy. 7. Response rate in the 3rd-line chemotherapy. 8. Correlation among the measured results in renal function by different methods. | — |
Countries
Japan
Contacts
Public ContactDaishi Ichioka
Faculty of Medicine, University of Tsukuba Department of Urology
Outcome results
None listed